Suven Life Sciences Limited — Board Meeting, 13-05-2025: Outcome of Board Meeting

Suven Life Sciences has announced a board meeting to approve a capital raise of up to ₹858 Cr via preferential issue of 6.4 crore convertible warrants at ₹134 each. The funding will come from Promoter Group and select institutional and private investors, reinforcing the company’s financial strength and growth plans. No updates on dividends or operational changes were shared. This move highlights strong investor confidence ahead.